Net Loss per Share - Schedule of computation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Numerator
Net loss		$ (36,909)	$ (67,486)
Less: Net loss attributable to noncontrolling interest		$ (27,244)
Antidilutive securities
Earnout shares		17,500,000
Legacy SCS Restricted Share Units		50,000
Stock options granted under the 2022 Equity Incentive Plan		14,591,415
Restricted Stock Rights
Antidilutive securities
Unvested Restricted Stock Rights		6,175,541
Common Class A [Member]
Numerator
Net Loss		$ (9,665)	$ (67,486)
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Basic		(9,665)
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Diluted		$ (9,665)
Denominator
Weighted Average Shares Outstanding, Basic	[1]	61,540,231
Weighted Average Shares Outstanding, Diluted	[1]	61,540,231
Net loss per share attributable to Class A ordinary shares, Basic	[1]	$ (0.16)
Net loss per share attributable to Class A ordinary shares, Diluted	[1]	$ (0.16)
Common Class B [Member]
Antidilutive securities
ProKidney Corp. Ordinary Shares		173,444,861

[1] (1) The Company analyzed the calculation of net loss per share for periods prior to the Business Combination, as defined in Note 1, on July 11, 2022 and determined that it resulted in values that would not be meaningful to the users of the consolidated financial statements, as the capital structure completely changed as a result of the Business Combination. Therefore, net loss per share information has not been presented for periods prior to the Business Combination. For more information refer to Note 8.